EUVIMEDEUVIMED entdecken
Crossref

Hesperidin PLGA nanoparticles potentiate the efficacy of aPD-1 in treating triple negative breast cancer by regulating CCL2 and ADPN expression in cancer-associated adipocytes

Ningchao Luo, Lisha Ma, Ninghui Ma, Jiale Wei, Hongyan Zhang, Wanyu Jin, Yujie Li, Jingbin Shi, Yang Xiong

International Immunopharmacology · 2024

DOI: 10.1016/j.intimp.2024.112759 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Immunopharmacology, 2024. Verfasst von Ningchao Luo und 8 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou, Zhejiang 310053, China. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Hesperidin, Nanoparticles, Chemokine CCL2. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 41 Literaturangaben. Gefördert von: Natural Science Foundation of Zhejiang Province, Zhejiang Chinese Medical University, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Triple negative breast cancer (TNBC) represents a heterogeneous subtype of breast cancer characterized by an unfavorable prognosis due to its aggressive biology. Cancer-associated adipocytes (CAAs) play an active role in tumor development, invasion and metastasis, and response to treatment by secreting various cytokines. CAAs secrete CCL2 and ADPN which significantly affect the efficacy of aPD-1 in treating breast cancer. Our recent research has demonstrated that Hesperidin, a natural phenolic compound, significantly inhibits CCL2, elevates ADPN secreted by CAAs in vitro and in vivo, remodels the immune microenvironment, and potentiates the efficacy of aPD-1 in triple-negative breast cancer. We used Oil red staining, Bodipy 493/503 staining and quantitative real-time PCR to verify the formation of CAAs. ELISA was used to detect levels of CCL2, ADPN secreted by CAAs. Changes in the number of immune cells in mouse tumor tissues were detected using flow cytometry and immunofluorescence. Our data suggest that Hesperidin PLGA nanoparticles significantly reduced CCL2 and increased ADPN secreted by CAAs, which concurrently decreased the recruitment of M2 macrophages, Tregs and MDSCs while increased the infiltration of CD8+T cells, M1 macrophages and DCs into tumor, thus significantly potentiated the efficacy of aPD-1 in vivo. This study provides a new combined strategy for the clinical treatment of triple-negative breast cancer by interfering with CCL2, ADPN secreted by CAAs to enhance the efficacy of immunotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Triple Negative Breast NeoplasmsHesperidinNanoparticlesChemokine CCL2AdipocytesAnimalsFemaleHumansCell Line, TumorMicePolylactic Acid-Polyglycolic Acid CopolymerTumor MicroenvironmentMice, Inbred BALB CAdipokinesGene Expression Regulation, NeoplasticDrug Synergism

Stichwörter der Autor:innen

ADPNCCL2Cancer-associated adipocytesHesperidinTNBC

Substanzen

HesperidinChemokine CCL2Polylactic Acid-Polyglycolic Acid CopolymerAdipokines

Autor:innen und Institutionen

  • School of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou, Zhejiang 310053, China.
  • School of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou, Zhejiang 310053, China; Academy of Chinese Medical Science, Zhejiang Chinese Medical University, Hangzhou, Zhejiang 310053, China.
  • School of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou, Zhejiang 310053, China; Academy of Chinese Medical Science, Zhejiang Chinese Medical University, Hangzhou, Zhejiang 310053, China. Electr…

Förderung

  • Natural Science Foundation of Zhejiang Province
  • Zhejiang Chinese Medical University
  • National Natural Science Foundation of China

Zitieren

APA

Luo, N., Ma, L., Ma, N., Wei, J., Zhang, H., Jin, W., Li, Y., Shi, J., & Xiong, Y. (2024). Hesperidin PLGA nanoparticles potentiate the efficacy of aPD-1 in treating triple negative breast cancer by regulating CCL2 and ADPN expression in cancer-associated adipocytes. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2024.112759

Vancouver

Luo N, Ma L, Ma N, Wei J, Zhang H, Jin W, et al. Hesperidin PLGA nanoparticles potentiate the efficacy of aPD-1 in treating triple negative breast cancer by regulating CCL2 and ADPN expression in cancer-associated adipocytes. International Immunopharmacology. 2024. doi:10.1016/j.intimp.2024.112759

BibTeX
@article{Luo2024,
  author = {Luo, Ningchao and Ma, Lisha and Ma, Ninghui and Wei, Jiale and Zhang, Hongyan and Jin, Wanyu and Li, Yujie and Shi, Jingbin and Xiong, Yang},
  title = {Hesperidin PLGA nanoparticles potentiate the efficacy of aPD-1 in treating triple negative breast cancer by regulating CCL2 and ADPN expression in cancer-associated adipocytes},
  journal = {International Immunopharmacology},
  year = {2024},
  doi = {10.1016/j.intimp.2024.112759}
}
Kostenlos starten →